Mobile healthcare apps and social media become platform for user-centric revolution enabling people to take charge of their health
CAESAREA, Israel, November 16, 2015 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced that Facebook (NASDAQ:FB) published a case study about the Company’s social media marketing campaign for the Dario on Facebook for Business’ Success Story series. To view the case study visit: https://www.facebook.com/business/success/dario
In the case study titled, “This little meter went to market,” Facebook writes, “A targeted campaign for a new-to-the-market pocket diabetes smart meter not only created awareness and sales leads, but also fostered a supportive and engaged online community.”
As a result of the three month social media campaign on Facebook, LabStyle doubled its online sales and tripled its sales in Australia.
“LabStyle is on the forefront of delivering technology that empowers people to take charge of their health. This is a truly user-centric healthcare revolution. Through online engagement of Dario users, we’ve created an information sharing network of supportive, like-minded people living with diabetes who are empowered and thriving,” stated Erez Raphael, LabStyle’s Chairman and Chief Executive Officer. “Working on social media platforms such as Facebook is a natural extension of our mobile app-based healthcare solutions. The Dario has been extremely well received in the glucose monitoring market and we intend to introduce similar apps for other indications where patients can similarly benefit from being fully in control of their own monitoring and engaging in a community of users.”
According to mhealthshare mobile health apps will generate $26.5 billion in revenues in 2017.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: www.mydario.com and http://mydario.investorroom.com. the content of which is not part of this press release
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. For example, we are using forward looking statements in this press release when we discuss mobile health apps projected revenues and our intention to introduce similar apps for other indications where patients can similarly benefit from being fully in control of their own monitoring and engaging in a community of users. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Press and Investor Relations
|1 800 896 9062|